menu

Loading...

TVGN Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

0.264

Open

0.260

VWAP

0.25

Vol

329.62K

Mkt Cap

50.14M

Low

0.244

Amount

83.23K

EV/EBITDA(TTM)

--

Total Shares

201.52M

EV

67.06M

EV/OCF(TTM)

--

P/S(TTM)

--

Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.

Show More

Events Timeline

(ET)

2026-02-27

14:30:00

Tevogen Signs Letter of Intent for Potential Transaction with Global CRO

2026-02-26 (ET)

2026-02-26

09:30:00

Tevogen Signs Letter of Intent to Evaluate Transaction with Sciometrix

2026-01-30 (ET)

2026-01-30

15:10:00

Tevogen Considers Special Cash Dividend for Shareholders

2026-01-12 (ET)

2026-01-12

09:10:00

Tevogen Reports Significant Biotechnology Milestones Achieved in 2025

2025-11-05 (ET)

2025-11-05

15:24:14

Tevogen Achieves Key Clinical Milestone in Development of ExacTcell Platform

2025-10-15 (ET)

2025-10-15

15:52:09

Tevogen Offers Update on TVGN 489 in Response to Interest from Long COVID Patients

2025-09-25 (ET)

2025-09-25

08:41:00

Tevogen Reports Major Advancements in the Development of the PredicTcell Platform

2025-09-23 (ET)

2025-09-23

08:33:51

Tevogen emphasizes the possible significance of TVGN 489 in addressing Long COVID effects.

2025-09-09 (ET)

2025-09-09

15:18:07

Tevogen projects a $6.5 billion revenue forecast for TVGN 116 over the next five years.

2025-09-08 (ET)

2025-09-08

09:30:30

Tevogen Estimates rNPV of TVGN-480 Between $9 Billion and $11 Billion

News

Newsfilter

02-27Newsfilter

Tevogen Signs Letter of Intent with Global CRO

Newsfilter

02-26Newsfilter

Tevogen Enters Letter of Intent with Sciometrix for Potential Acquisition

Newsfilter

02-26Newsfilter

Tevogen Signs Letter of Intent with Sciometrix for Potential Acquisition

moomoo

TEVOGEN BIO HOLDINGS INC - AGREEMENT MAY TRANSFORM TEVOGEN INTO A PROFITABLE HEALTHCARE BUSINESS

moomoo

TEVOGEN ENTERS LETTER OF INTENT TO ASSESS POSSIBLE ACQUISITION OF SCIOMETRIX AND ITS DIGITAL CARE MANAGEMENT PLATFORM, CLINICUS

Newsfilter

01-30Newsfilter

Tevogen Evaluates Potential Special Cash Dividend

Valuation Metrics

The current forward P/E ratio for Tevogen Bio Holdings Inc (TVGN.O) is -1.80, compared to its 5-year average forward P/E of -0.93. For a more detailed relative valuation and DCF analysis to assess Tevogen Bio Holdings Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-0.93

Current PE

-1.80

Overvalued PE

0.81

Undervalued PE

-2.67

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Whales Holding TVGN

Trading Trends

People Also Watch

Frequently Asked Questions

What is Tevogen Bio Holdings Inc (TVGN) stock price today?

The current price of TVGN is 0.2488 USD — it has decreased -5.68

What is Tevogen Bio Holdings Inc (TVGN)'s business?

Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.

What is the price predicton of TVGN Stock?

Wall Street analysts forecast TVGN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TVGN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Tevogen Bio Holdings Inc (TVGN)'s revenue for the last quarter?

Tevogen Bio Holdings Inc revenue for the last quarter amounts to -5.73M USD, decreased -5.85

What is Tevogen Bio Holdings Inc (TVGN)'s earnings per share (EPS) for the last quarter?

Tevogen Bio Holdings Inc. EPS for the last quarter amounts to USD, decreased

How many employees does Tevogen Bio Holdings Inc (TVGN). have?

Tevogen Bio Holdings Inc (TVGN) has 18 emplpoyees as of March 03 2026.

What is Tevogen Bio Holdings Inc (TVGN) market cap?

Today TVGN has the market capitalization of 50.14M USD.